These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22971934)

  • 1. Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.
    Yang H; Nkeze J; Zhao RY
    Cell Biosci; 2012 Sep; 2(1):32. PubMed ID: 22971934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
    Benko Z; Zhang J; Zhao RY
    Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (
    Zhang J; Vernon K; Li Q; Benko Z; Amoroso A; Nasr M; Zhao RY
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34202872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fission yeast cell-based system for multidrug resistant HIV-1 proteases.
    Benko Z; Liang D; Li G; Elder RT; Sarkar A; Takayama J; Ghosh AK; Zhao RY
    Cell Biosci; 2017; 7():5. PubMed ID: 28096973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells.
    Mavian C; Coman RM; Zhang X; Pomeroy S; Ostrov DA; Dunn BM; Sleasman JW; Goodenow MM
    J AIDS Clin Res; 2021; 12(5):. PubMed ID: 34950525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
    Weber J; Mesters JR; Lepsík M; Prejdová J; Svec M; Sponarová J; Mlcochová P; Skalická K; Strísovský K; Uhlíková T; Soucek M; Machala L; Stanková M; Vondrásek J; Klimkait T; Kraeusslich HG; Hilgenfeld R; Konvalinka J
    J Mol Biol; 2002 Dec; 324(4):739-54. PubMed ID: 12460574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
    Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
    J Comput Aided Mol Des; 2018 Mar; 32(3):459-471. PubMed ID: 29397520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives.
    Zha W; Zha BS; Zhou F; Zhou H; Wang G
    Curr Drug Metab; 2012 Oct; 13(8):1174-83. PubMed ID: 22746305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
    Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
    Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.